Rasagiline

Rasagiline is an irreversible inhibitor of monoamine oxidase-B used as a monotherapy to treat symptoms in early Parkinson's disease or as an adjunct therapy in more advanced cases.

Rasagiline

Rasagiline; 136236-51-6; (R)-N-(2-Propynyl)-2,3-dihydroinden-1-amine; (R)-2,3-dihydro-N-2-propynyl-1H-inden-1-amine; Rasagiline [INN]; (R)-N-2-Propynyl-1-indanamine

Relgin

(1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine

NA

NA

As a monotherapy, start with an initial oral dose of 1 mg/day.

For the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa.

Lack of coordination, malignant hypertension, hemiplegia, agitation, flu-like symptoms, speech anomalies, hallucination, overactive reflexes, diarrhoea, tics, and loss of libido, nightmares, impotence, GI upset, nausea and behavioural changes.

• Rasagiline may interact with several drugs including cyclobenzarapine, dextromethorphan, fluoroquinolones, OTC anti-tussives, anti-depressive drugs, meperidine, St. John’s wort, tramadol, methadone, St. John’s wort, cyclobenzaprine and other MAOIs.
• Avoid consuming cheese while taking Rasagiline.

Rasagiline is contraindicated in individuals with liver diseases, melanoma and Parkinson’s disease.

Store at 20-25°C.

Molecular weight

171.2383

Molecular formula

C12H13N

CAS number

136236-51-6

Precautions

NA